Ad Tech Holdings Limited

Other

Iasomai Ab

Pep-Tonic Medical Ab

Entretech Medical Ab

Adtech Holding

Thomas Lundeberg

Billy Valter Sodervall

Kerstin Uvnäs-Moberg

Tiziana Parasassi

Eugenia Pittaluga

Kerstin Uvnäs Moberg

Maria Petersson

Roberto Brunelli

Kerstin Uvn&auml;s-Moberg

The invention relates to a new use of NAC in IVF, in a human or mammalian animal patient. In addition an effective dose regimen of NAC in IVF is proposed.

N-acetyl-L-cysteine for use in in vitro fertilization

The present invention relates to the use of substances with oxytocin activity against climacteric disorders or similar symptoms due to dysfunction in the ovaries. It also relates to a pharmaceutical composition comprising at least one substance with oxytocin activity against climacteric disorders.

Use of substances with oxytocin activity against climacteric disorders

The present invention relates to the use di-, tri- and tetrapeptide fragments of oxytocin or mesotocin for the preparation of a pharmaceutical composition in order to create eustasis. The invention also relates to di-, tri- and tetrapeptide fragments of oxytocin or mesotocin for medical use, as well as a pharmaceutical composition comprising at least one di-, tri- or tetrapeptide fragment of oxytocin or mesotocin in order to create eustasis.

Use of fragments of oxytocin for the preparation of a pharmaceutical composition in order to create eustasis

A method of treating cancer in situ and cervicitis is disclosed. A pharmaceutical composition comprising at least one substance with oxytocin activity against cancer in situ and cervicitis and compound of the formula SEQ ID NO:2 is also disclosed.

Use of oxytocin for the preparation of a pharmaceutical composition against cancer in situ and cervicitis

Substances having oxytocin activity can be used for the preparation of a pharmaceutical composition for the curative or prophylactic treatment of wounds, such as chronic wounds. The wound healing effect can be strengthened or prolonged by combining oxytocin with estrogen.

Use of substances having oxytocin activity for preparation of medicaments for wound healing

Metallic silver is deposited upon the surface of a nonconducting substrate using a multi-step wet deposition process. The surface is cleaned, and then activated in an aqueous solution containing stannous tin. The silver is deposited as a colloidal material from an aqueous solution of a silver-containing salt, a reduction agent that reduces the salt to form the metallic silver, and a deposition control agent that prevents the silver from nucleating throughout the solution. After the substrate is coated, the coating is stabilized in an aqueous solution of a salt of a metal from the platinum group or gold, dissolved in dilute hydrochloric acid. The process is particularly effective for depositing uniform-films of 2 to 2000 Angstroms thickness, which strongly adhere to the substrate.

Deposition of silver layer on nonconducting substrate

Metallic silver is deposited upon the surface of a nonconducting substrate using a multi-step wet deposition process. The surface is cleaned, and then activated in an aqueous solution containing stannous tin. The silver is deposited as a colloidal material from an aqueous solution of a silver-containing salt, a reduction agent that reduces the salt to form the metallic silver, and a deposition control agent that prevents the silver from nucleating throughout the solution. After the substrate is coated, the coating is stabilized in an aqueous solution of a salt of a metal from the platinum group or gold, dissolved in dilute hydrochloric acid. The process is particularly effective for depositing uniform films of 2 to 2000 Angstroms thickness, which strongly adhere to the substrate.

A thin silver layer is deposited on the surface of a nonconducting substrate using an electroless process. The surface is cleaned and activated in aqueous solution containing stannous tin. The silver is deposited as a colloidal material from an aqueous solution of a silver-containing salt in the absence of an electric current, but in the presence of a deposition control agent. Optionally, the silver layer is stabilized with an aqueous solution of a platinum-group metal and/or gold. The resulting silver layer is uniform and of 2-2000 .ANG. thickness; it strongly adheres to the substrate.

Metallic silver is deposited upon the surface of a nonconducting substrate using a multi-step wet deposition process. The surface is cleaned, and then activated in an aqueous solution containing stannous tin. The silver is deposited as a colloidal material from an aqueous solution of a silver-containing salt, a reduction agent that reduces the salt to form the metallic silver, and a deposition control agent that prevents the silver from nucleating throughout the solution. After the substrate is coated, the coating is stabilized in an aqueous solution of a salt of a metal from the platinum group of gold, dissolved in dilute hydrochloric acid. The process is particularly effective for depositing uniform films of 2 to 2000 Angstroms thickness, which strongly adhere to the substrate.

Growing community of inventors

Lidingo, Sweden

Thomas Lundeberg